Neoadjuvant therapy with immune checkpoint inhibitors in combination with chemotherapy vs.chemotherapy alone in HER2(-)locally advanced gastric cancer:A propensity score-matched cohort studyOACSCDCSTPCD
Neoadjuvant therapy with immune checkpoint inhibitors in combination with chemotherapy vs.chemotherapy alone in HER2(-)locally advanced gastric cancer:A propensity score-matched cohort study
Gehan Xu;Tianjiao Liu;Jingyi Shen;Quanlin Guan
The First Clinical Medical College of Lanzhou University,Lanzhou,Gansu 730000,ChinaDepartment of Medical Data,Beijing Yiyong Technology Co.,Ltd.,Beijing 100102,ChinaThe First Clinical Medical College of Lanzhou University,Lanzhou,Gansu 730000,ChinaDepartment of Oncology Surgery,The First Hospital of Lanzhou University,Lanzhou,Gansu 730000,China
Gastric cancerNeoadjuvant therapyImmune checkpoint inhibitorChemotherapyPropensity score matching
Gastric cancerNeoadjuvant therapyImmune checkpoint inhibitorChemotherapyPropensity score matching
《中华医学杂志（英文版）》 2025 (4)
459-471,13
This work was supported by grants from the Gansu Provincial Key Research and Development Project-Social Development Category(No.20YF3FA029),the Gansu Science and Technology Project(No.20JR10RA672),and the First Hospital of Lanzhou University Hospital Fund(No.ldyyyn2021-1).
评论